Broccoli has been consumed around the world in various ways; either raw, blanched, frozen, dehydrated or fermented; however, functional foods and nutraceuticals are currently being designed and marketed from broccoli, through the extraction of compounds such as sulforaphane, which according to several studies and depending on its bioavailability has a protective effect on some types of cancer. Likewise, several food technologies are reported to seek to offer innovative foods to increasingly careful and critical consumers, ensuring that they retain their nutritional and sensory attributes even after processing and that they are also safe. In this sense, studies on the effect of processing on compounds of interest to health are of great relevance. Therefore, this article presents an overview on the study of traditionally consumed broccoli and the design of new products from the use of agro-industrial residues that, due to their high content of fiber and fitochemical compounds, can benefit the quality of life of the human population.

The main reason for the formation of nano-biotechnology is due to the penetration of nanotechnology in the biological field, nanotechnology research center is the study of nano-drug carrier. Nano-drug system targeted drug delivery to achieve drug release, increase the insoluble drugs and peptide drug bio-efficiency, reduce the toxicity and application of drugs and other aspects of the development of good prospects, and thus become one of the key research in recent years’ field. Synthesis and application of nanometer drug carriers this review is presented in recent years and its application to provide a comprehensive basis for the treatment process. Describes the nature and preparation of nano-drug carrier methods, in recent years, people have been widely concerned by scholars. Compared with the nano-drug delivery, the general pharmaceutical cannot have to extend the role of drugs, strong efficacy, and the advantages of small drug response. Nano-materials, the specific surface area, surface activity, high catalytic efficiency, surface active center, adsorption capacity and other characteristics, which has many excellent features and new features.

This work investigates epoxy composites reinforced by randomly oriented, short glass fibres and silica microparticles. A full-factorial experiment evaluates the effects of glass fibre mass fraction (15 wt% and 20 wt%) and length (5 mm and 10 mm), and the mass fraction of silica microparticles (5 wt% and 10 wt%) on the apparent density and porosity, as well as the compressive and tensile strength and modulus of the hybrid composites. Hybrid epoxy composites present significantly higher tensile strength (9%) and modulus (57%), as well as compressive strength (up to 15%) relative to pure epoxy.

Learning from experience to improve future infrastructure public-private partnerships is a focal issue for policy makers, financiers, implementers, and private sector stakeholders. An extensive body of case studies and “lessons learned” aims to improve the likelihood of success and attempts to avoid future contract failures across sectors and geographies. This paper examines whether countries do, indeed, learn from experience to improve the probability of success of public-private partnerships at the national level. The purview of the paper is not to diagnose learning across all aspects of public-private partnerships globally, but rather to focus on whether experience has an effect on the most extreme cases of public-private partnership contract failure, premature contract cancellation. The analysis utilizes mixed-effects probit regression combined with spline models to test empirically whether general public-private partnership experience has an impact on reducing the chances of contract cancellation for future projects. The results confirm what the market intuitively knows, that is, that public-private partnership experience reduces the likelihood of contract cancellation. But the results also provide a perhaps less intuitive finding: the benefits of learning are typically concentrated in the first few public-private partnership deals. Moreover, the results show that the probability of cancellation varies across sectors and suggests the relative complexity of water public-private partnerships compared with energy and transport projects. An estimated $1.5 billion per year could have been saved with interventions and support to reduce cancellations in less experienced countries (those with fewer than 23 prior public-private partnerships).

Researchers from all over the world have been working tirelessly to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic since the World Health Organization (WHO) proclaimed it to be a pandemic in 2019. Expanding testing capacities, creating efficient medications, and creating safe and efficient COVID-19 (SARS CoV-2) vaccinations that provide the human body with long-lasting protection are a few tactics that need to be investigated. In clinical studies, drug delivery techniques, including nanoparticles, have been used since the early 1990s. Since then, as technology has advanced and the need for improved medication delivery has increased, the field of nanomedicine has recently seen significant development. PNPs, or polymeric nanoparticles, are solid particles or particulate dispersions that range in size from 10 to 1000 nm, and their ability to efficiently deliver therapeutics to specific targets makes them ideal drug carriers. This review article discusses the many polymeric nanoparticle (PNP) platforms developed to counteract the recent COVID-19 pandemic-related severe acute respiratory syndrome coronavirus (SARS-CoV-2). The primary subjects of this article are the size, shape, cytotoxicity, and release mechanism of each nanoparticle. The two kinds of preparation methods in the synthesis of polymeric nanoparticles have been discussed: the first group uses premade polymers, while the other group depends on the direct polymerization of monomers. A few of the PNPs that have been utilized to combat previous viral outbreaks against SARS-CoV-2 are also covered.